

## Event Calendar - 2024 Events

### **Kepler Cheuvreux Swiss Seminar**

March 20, 2025  
Zurich, Switzerland

### **Barclays Healthcare Conference**

March 12, 2025  
Miami, USA

### **Annual General Meeting**

March 07, 2025  
Basel, Switzerland

[Visit the General Meetings section](#)

### **Cowen Healthcare Conference**

March 04, 2025  
Boston, USA

### **UBS European Healthcare Conference**

March 04, 2025  
London, UK

### **J.P. Morgan Healthcare Conference**

January 14, 2025  
San Francisco, USA

Novartis CEO Vas Narasimhan presented at the J.P. Morgan Healthcare Conference.

[Download the presentation \(PDF 2.3 MB\)](#)

[Download the podcast \(MP3 18 MB\)](#)

### **Impact and Sustainability**

December 09, 2024  
Virtual event

Novartis 11th annual ESG investor event

[Watch the webcast](#)

[Download the presentation \(PDF 1.9 MB\)](#)

## **Citi Global Healthcare Conference**

December 04, 2024

Miami, USA

## **Meet Novartis Management**

November 21, 2024

London, UK

[Read the media release](#)

[Watch the webcast](#)

[Download the webcast agenda \(PDF 0.1 MB\)](#)

[Download the speaker slides \(PDF 0.8 MB\)](#)

[Download the CEO presentation \(PDF 1.2 MB\)](#)

[Download the breakout slides \(PDF 0.3 MB\)](#)

## **UBS European Conference**

November 13, 2024

London, UK

## **UBS Global Healthcare Conference**

November 12, 2024

Ranchos Palo Verdes, USA

## **Guggenheim Global Healthcare Conference**

November 12, 2024

Boston, USA

## **ZKB Swiss Equity Conference Zurich**

November 08, 2024

Zurich, Switzerland

## **Third quarter results 2024**

October 29, 2024

Basel, Switzerland

Media release:

[English \(PDF 0.4 MB\)](#) | [Deutsch \(PDF 0.5 MB\)](#)

[Interim financial report \(PDF 0.6 MB\)](#)

---

[Watch the webcast](#)

[Download the podcast \(MP3 31 MB\)](#)

[Download the presentation \(PDF 6.8 MB\)](#)

[Read the transcript](#)

[Novartis Q3 2024 impact and sustainability update \(PDF 0.6 MB\)](#)

## **Renal Portfolio Update**

October 28, 2024

Virtual

[Download the presentation \(PDF 1.4 MB\)](#)

[Watch the webcast](#)

[Download the podcast \(MP3 30 MB\)](#)

## **Baader Investment Conference**

September 26, 2024

Munich, Germany

## **BNP Paribas Exane ESG Conference**

September 25, 2024

Paris, France

## **Bank of America Merrill Lynch Global Healthcare Conference**

September 18, 2024

London, UK

## **Morgan Stanley Global Healthcare Conference**

September 05, 2024

New York, USA

## **Second quarter results 2024**

July 18, 2024

Basel, Switzerland

Media release:

[English \(PDF 0.5 MB\)](#) | [Deutsch \(PDF 0.5 MB\)](#) | [Français \(PDF 0.5 MB\)](#)

[Interim financial report \(PDF 0.5 MB\)](#)

---

[Watch the webcast](#)

[Download the podcast \(MP3 34 MB\)](#)

[Download the presentation \(PDF 5.5 MB\)](#)

[Read the transcript](#)

[Novartis Q2 2024 impact and sustainability update \(PDF 0.9 MB\)](#)

### **Stifel European Healthcare Summit**

June 27, 2024

Lyon, France

### **J.P. Morgan European Healthcare Conference**

June 20, 2024

London, UK

### **Citi European Healthcare Conference**

June 19, 2024

London, UK

### **Goldman Sachs Global Healthcare Conference**

June 11, 2024

Miami, USA

### **Jefferies Global Healthcare Conference**

June 06, 2024

New York, USA

### **Novartis ASCO Investor Event**

June 02, 2024

Chicago, USA

[Watch the webcast](#)

[Download the presentation \(PDF 1.0 MB\)](#)

[Read the media release: Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML](#)

### **Bernstein Annual Strategic Decisions**

May 29, 2024

New York, USA

### **dbAccess European Champions Conference**

May 23, 2024

Frankfurt, Germany

### **Berenberg European Conference**

May 21, 2024

New York, USA

### **Barclays European Select Conference**

May 20, 2024  
Brooklyn, USA

### **Redburn Atlantic Canada Conference**

May 15, 2024  
Toronto, Canada

### **Bank of America Healthcare Conference**

May 15, 2024  
Las Vegas, USA

### **First quarter results 2024**

April 23, 2024  
Basel, Switzerland

Media release:

[English \(PDF 0.3 MB\)](#) | [Deutsch \(PDF 0.3 MB\)](#) | [Français \(PDF 0.4 MB\)](#)

[Interim financial report \(PDF 0.4 MB\)](#)

---

[Watch the webcast](#)

[Download the podcast \(MP3 30 MB\)](#)

[Download the presentation \(PDF 6.0 MB\)](#)

[Read the transcript](#)

[Novartis Q1 2024 impact and sustainability update \(PDF 1.4 MB\)](#)

### **BNP Paribas Exane Healthcare Conference**

March 26, 2024  
Virtual

### **Societe Generale European ESG-SRI Conference**

March 26, 2024  
Paris, France

### **Kepler Cheuvreux Swiss Seminar**

March 21, 2024  
Zurich, Switzerland

### **Cowen Conference**

March 06, 2024  
Boston, USA

### **Annual General Meeting**

March 05, 2024  
Basel, Switzerland

[Visit the General Meetings section](#)

## **UBS European Healthcare Conference**

February 28, 2024  
London, UK

## **Fourth quarter and full year results 2023 and Annual Report 2023 publication**

January 31, 2024  
Basel, Switzerland

Media release:

[English \(PDF 0.3 MB\)](#) | [Deutsch \(PDF 0.3 MB\)](#) | [Français \(PDF 0.3 MB\)](#)

[Condensed financial report \(PDF 0.6 MB\)](#)

---

[Download the podcast \(MP3 34 MB\)](#)

[Download the presentation \(PDF 5.5 MB\)](#)

[Read the transcript](#)

[Novartis Q4 2023 impact and sustainability update \(PDF 0.6 MB\)](#)

[2023 epidemiology data \(PDF 1.1 MB\)](#)

## **J.P. Morgan Healthcare Conference**

January 08, 2024  
San Francisco, USA

[Download the presentation \(PDF 1.3 MB\)](#)

[Download the podcast \(MP3 18 MB\)](#)

[Read the featured news](#)

---

**Source URL:** <https://prod1.novartis.com/node/662281>

## **List of links present in page**

1. <https://prod1.novartis.com/node/662281>
2. <https://prod1.novartis.com/investors/shareholder-information/general-meetings>
3. [https://prod1.novartis.com/sites/novartis\\_com/files/novartis-investor-presentation-jpm-2025-growth-story.pdf](https://prod1.novartis.com/sites/novartis_com/files/novartis-investor-presentation-jpm-2025-growth-story.pdf)
4. [https://prod1.novartis.com/sites/novartis\\_com/files/2025-01/novartis-investor-presentation-jpm-2025-growth-story.mp3](https://prod1.novartis.com/sites/novartis_com/files/2025-01/novartis-investor-presentation-jpm-2025-growth-story.mp3)
5. [https://novartis.webcasts.com/starthere.jsp?ei=1689776&tp\\_key=9312b9a422](https://novartis.webcasts.com/starthere.jsp?ei=1689776&tp_key=9312b9a422)
6. [https://prod1.novartis.com/sites/novartis\\_com/files/2024-12-novartis-impact-sustainability.pdf](https://prod1.novartis.com/sites/novartis_com/files/2024-12-novartis-impact-sustainability.pdf)
7. <https://prod1.novartis.com/news/media-releases/novartis-upgrades-mid-term-guidance-and-highlights-6/8>

deep-pipeline-core-therapeutic-areas-drive-long-term-growth

8. <https://edge.media-server.com/mmc/p/mfs4d9bz>
9. [https://prod1.novartis.com/sites/novartis\\_com/files/meet-novartis-management-2024-agenda.pdf](https://prod1.novartis.com/sites/novartis_com/files/meet-novartis-management-2024-agenda.pdf)
10. [https://prod1.novartis.com/sites/novartis\\_com/files/meet-novartis-management-2024-speaker-slides.pdf](https://prod1.novartis.com/sites/novartis_com/files/meet-novartis-management-2024-speaker-slides.pdf)
11. [https://prod1.novartis.com/sites/novartis\\_com/files/meet-novartis-management-2024-ceo-presentation.pdf](https://prod1.novartis.com/sites/novartis_com/files/meet-novartis-management-2024-ceo-presentation.pdf)
12. [https://prod1.novartis.com/sites/novartis\\_com/files/meet-novartis-management-2024-breakout-slides.pdf](https://prod1.novartis.com/sites/novartis_com/files/meet-novartis-management-2024-breakout-slides.pdf)
13. [https://prod1.novartis.com/sites/novartis\\_com/files/q3-2024-media-release-en.pdf](https://prod1.novartis.com/sites/novartis_com/files/q3-2024-media-release-en.pdf)
14. [https://prod1.novartis.com/sites/novartis\\_com/files/q3-2024-media-release-de.pdf](https://prod1.novartis.com/sites/novartis_com/files/q3-2024-media-release-de.pdf)
15. [https://prod1.novartis.com/sites/novartis\\_com/files/2024-10-interim-financial-report-en.pdf](https://prod1.novartis.com/sites/novartis_com/files/2024-10-interim-financial-report-en.pdf)
16. <https://edge.media-server.com/mmc/p/3hrspsa4>
17. [https://prod1.novartis.com/sites/novartis\\_com/files/2024-10/q3-2024-investor-presentation.mp3](https://prod1.novartis.com/sites/novartis_com/files/2024-10/q3-2024-investor-presentation.mp3)
18. [https://prod1.novartis.com/sites/novartis\\_com/files/q3-2024-investor-presentation.pdf](https://prod1.novartis.com/sites/novartis_com/files/q3-2024-investor-presentation.pdf)
19. <https://prod1.novartis.com/investors/financial-data/quarterly-results/2024-q3-transcript>
20. [https://prod1.novartis.com/sites/novartis\\_com/files/novartis-q3-2024-impact-and-sustainability-update.pdf](https://prod1.novartis.com/sites/novartis_com/files/novartis-q3-2024-impact-and-sustainability-update.pdf)
21. [https://prod1.novartis.com/sites/novartis\\_com/files/2024-10-novartis-renal-portfolio-presentation.pdf](https://prod1.novartis.com/sites/novartis_com/files/2024-10-novartis-renal-portfolio-presentation.pdf)
22. <https://edge.media-server.com/mmc/p/d4yyo26k>
23. [https://prod1.novartis.com/sites/novartis\\_com/files/2024-10/2024-10-novartis-renal-portfolio-presentation.mp3](https://prod1.novartis.com/sites/novartis_com/files/2024-10/2024-10-novartis-renal-portfolio-presentation.mp3)
24. [https://prod1.novartis.com/sites/novartis\\_com/files/q2-2024-media-release-en.pdf](https://prod1.novartis.com/sites/novartis_com/files/q2-2024-media-release-en.pdf)
25. [https://prod1.novartis.com/sites/novartis\\_com/files/q2-2024-media-release-de.pdf](https://prod1.novartis.com/sites/novartis_com/files/q2-2024-media-release-de.pdf)
26. [https://prod1.novartis.com/sites/novartis\\_com/files/q2-2024-media-release-fr.pdf](https://prod1.novartis.com/sites/novartis_com/files/q2-2024-media-release-fr.pdf)
27. [https://prod1.novartis.com/sites/novartis\\_com/files/2024-07-interim-financial-report-en.pdf](https://prod1.novartis.com/sites/novartis_com/files/2024-07-interim-financial-report-en.pdf)
28. <https://edge.media-server.com/mmc/p/a2y6rkfr>
29. [https://prod1.novartis.com/sites/novartis\\_com/files/2024-07/q2-2024-investor-presentation.mp3](https://prod1.novartis.com/sites/novartis_com/files/2024-07/q2-2024-investor-presentation.mp3)
30. [https://prod1.novartis.com/sites/novartis\\_com/files/q2-2024-investor-presentation.pdf](https://prod1.novartis.com/sites/novartis_com/files/q2-2024-investor-presentation.pdf)
31. <https://prod1.novartis.com/investors/financial-data/quarterly-results/2024-q2-transcript>
32. [https://prod1.novartis.com/sites/novartis\\_com/files/novartis-q2-2024-impact-and-sustainability-update.pdf](https://prod1.novartis.com/sites/novartis_com/files/novartis-q2-2024-impact-and-sustainability-update.pdf)
33. <https://edge.media-server.com/mmc/p/3xi5zz7j/>
34. [https://prod1.novartis.com/sites/novartis\\_com/files/2024-novartis-asco-investor-event-presentation.pdf](https://prod1.novartis.com/sites/novartis_com/files/2024-novartis-asco-investor-event-presentation.pdf)
35. <https://prod1.novartis.com/news/media-releases/novartis-scemblix-phase-iii-data-first-show-superior-efficacy-favorable-safety-and-tolerability-profile-vs-standard-care-tkis-adults-newly-diagnosed-cml>
36. [https://prod1.novartis.com/sites/novartis\\_com/files/q1-2024-media-release-en.pdf](https://prod1.novartis.com/sites/novartis_com/files/q1-2024-media-release-en.pdf)
37. [https://prod1.novartis.com/sites/novartis\\_com/files/q1-2024-media-release-de.pdf](https://prod1.novartis.com/sites/novartis_com/files/q1-2024-media-release-de.pdf)
38. [https://prod1.novartis.com/sites/novartis\\_com/files/q1-2024-media-release-fr.pdf](https://prod1.novartis.com/sites/novartis_com/files/q1-2024-media-release-fr.pdf)
39. [https://prod1.novartis.com/sites/novartis\\_com/files/2024-04-interim-financial-report-en.pdf](https://prod1.novartis.com/sites/novartis_com/files/2024-04-interim-financial-report-en.pdf)
40. <https://edge.media-server.com/mmc/p/dngt7jpp>
41. [https://prod1.novartis.com/sites/novartis\\_com/files/2024-04/q1-2024-investor-presentation.mp3](https://prod1.novartis.com/sites/novartis_com/files/2024-04/q1-2024-investor-presentation.mp3)
42. [https://prod1.novartis.com/sites/novartis\\_com/files/q1-2024-investor-presentation.pdf](https://prod1.novartis.com/sites/novartis_com/files/q1-2024-investor-presentation.pdf)
43. <https://prod1.novartis.com/investors/financial-data/quarterly-results/2024-q1-transcript>
44. [https://prod1.novartis.com/sites/novartis\\_com/files/novartis-q1-2024-impact-and-sustainability-update.pdf](https://prod1.novartis.com/sites/novartis_com/files/novartis-q1-2024-impact-and-sustainability-update.pdf)
45. <https://prod1.novartis.com/investors/shareholder-information/general-meetings>
46. [https://prod1.novartis.com/sites/novartis\\_com/files/q4-2023-media-release-en.pdf](https://prod1.novartis.com/sites/novartis_com/files/q4-2023-media-release-en.pdf)
47. [https://prod1.novartis.com/sites/novartis\\_com/files/q4-2023-media-release-de.pdf](https://prod1.novartis.com/sites/novartis_com/files/q4-2023-media-release-de.pdf)
48. [https://prod1.novartis.com/sites/novartis\\_com/files/q4-2023-media-release-fr.pdf](https://prod1.novartis.com/sites/novartis_com/files/q4-2023-media-release-fr.pdf)
49. [https://prod1.novartis.com/sites/novartis\\_com/files/2024-01-interim-financial-report-en.pdf](https://prod1.novartis.com/sites/novartis_com/files/2024-01-interim-financial-report-en.pdf)
50. [https://prod1.novartis.com/sites/novartis\\_com/files/2024-02/q4-2023-investor-presentation.mp3](https://prod1.novartis.com/sites/novartis_com/files/2024-02/q4-2023-investor-presentation.mp3)
51. [https://prod1.novartis.com/sites/novartis\\_com/files/q4-2023-investor-presentation.pdf](https://prod1.novartis.com/sites/novartis_com/files/q4-2023-investor-presentation.pdf)
52. <https://prod1.novartis.com/investors/financial-data/quarterly-results/2023-q4-and-full-year-results-transcript>
53. [https://prod1.novartis.com/sites/novartis\\_com/files/novartis-q4-2023-impact-and-sustainability-update.pdf](https://prod1.novartis.com/sites/novartis_com/files/novartis-q4-2023-impact-and-sustainability-update.pdf)
54. [https://prod1.novartis.com/sites/novartis\\_com/files/novartis-target-patient-populations-2023.pdf](https://prod1.novartis.com/sites/novartis_com/files/novartis-target-patient-populations-2023.pdf)
55. [https://prod1.novartis.com/sites/novartis\\_com/files/2024-jpm-novartis-strategy-growth-update.pdf](https://prod1.novartis.com/sites/novartis_com/files/2024-jpm-novartis-strategy-growth-update.pdf)
56. [https://prod1.novartis.com/sites/novartis\\_com/files/2024-01/2024-jpm-novartis-strategy-growth-update.mp3](https://prod1.novartis.com/sites/novartis_com/files/2024-01/2024-jpm-novartis-strategy-growth-update.mp3)

57. <https://prod1.novartis.com/news/jp-morgan-healthcare-conference-2024>
58. <https://prod1.novartis.com/node/662281/printable/print>
59. <https://prod1.novartis.com/node/662281/printable/pdf>